Koers Lexicon Pharmaceuticals, Inc. Nasdaq
Aandelen
US5288721047
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 24,2 mln. 22,47 mln. | Omzet 2025 * | 83,79 mln. 77,81 mln. | Marktkapitalisatie | 441 mln. 409 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -200 mln. -186 mln. | Nettowinst (verlies) 2025 * | -201 mln. -187 mln. | EV/omzet 2024 * | 18,2 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 5,26 x |
K/w-verhouding 2024 * |
-2,34
x | K/w-verhouding 2025 * |
-2,61
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,71% |
Recentste transcriptie over Lexicon Pharmaceuticals, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07-07-14 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01-01-99 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02-08-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-02-01 |
Ray Debbane
CHM | Chairman | 69 | 01-08-07 |
Director/Board Member | 65 | 28-08-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |